source
- Draig Therapeutics secures $65M Series B to advance brain-drug trialsDraig Therapeutics announced a $65 million Series B financing led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace and other investors. The capital will fund…
- Biogen's tau therapy shows mixed Alzheimer's results, low dose outperforms higher doseAt the Alzheimer's Association International Conference in London, Biogen presented data on its experimental tau‑targeting therapy for Alzheimer's disease. The trial showed that the drug produced…